MK-8962
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $1,080 | 4 | 2 |
| 2019 | $2,880 | 12 | 2 |
| 2018 | $3,200 | 2 | 2 |
| 2017 | $4,202 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $7,160 | 18 | 63.0% |
| Unspecified | $4,202 | 1 | 37.0% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A phase III, multi-center, open label, single-group trial to investigate the efficacy and safety of MK-8962 corifollitropin alfa in combination with human Chorionic Gonadotropin hCG for initiation or restoration of puberty as assessed by increased testicular volume in adolescent males 14 to 18 years old with hypogonadotropic hypogonadism | Merck Sharp & Dohme Corporation | $4,202 | 0 |
Manufacturing Companies
- Merck Sharp & Dohme Corporation $11,362
Product Information
- Type Biological
- Total Payments $11,362
- Total Doctors 2
- Transactions 19
About MK-8962
MK-8962 is a biological associated with $11,362 in payments to 2 healthcare providers, recorded across 19 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2020. In 2020, $1,080 was paid across 4 transactions to 2 doctors.
The most common payment nature for MK-8962 is "Consulting Fee" ($7,160, 63.0% of total).
MK-8962 is associated with 1 research study, including "A phase III, multi-center, open label, single-group trial to investigate the efficacy and safety of MK-8962 corifollitropin alfa in combination with human Chorionic Gonadotropin hCG for initiation or restoration of puberty as assessed by increased testicular volume in adolescent males 14 to 18 years old with hypogonadotropic hypogonadism" ($4,202).